BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
May 1, 2003
View Archived Issues
Genzyme, BioMarin Receive FDA's Aldurazyme Approval
Genzyme General and its partner, BioMarin Pharmaceutical Inc., received FDA approval for Aldurazyme, an enzyme replacement therapy for the treatment of a rare degenerative disease, mucopolysaccharidosis-1. (BioWorld Today)
Read More
Rigel Secures Agreements For $46 Million Private Placement
Read More
Bug's Chromosomal 5.2 Million Bases, 5,508 Genes In Plasmids Define Pathogenicity, Virulence
Read More
Post-Genomics Survival Demands Speed, Novelty, Broadened Scope
Read More
The Changing Face Of ImClone: Another Waksal Stepping Down
Read More
Other News To Note
Read More